Euroopa Liit -
eesti -
EMA (European Medicines Agency)
zalviso
fgk representative service gmbh - sufentaniil - valu, postoperatiivne - anesteetikumid - zalviso on näidustatud ägeda mõõduka kuni raske operatsioonijärgse valu raviks täiskasvanud.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
dovprela (previously pretomanid fgk)
mylan ire healthcare limited - pretomanid - tuberkuloos, multidrug-resistentne - antimükobakterid - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
kolbam
retrophin europe ltd - koliinhape - ainevahetus, kaasasündinud vead - vere ja maksa ravi - koolhape fgk on näidustatud ravi kaasasündinud vead esmase sapphappe sünteesi, imikutel alates ühe kuu vanuse pideva elukestva ravi läbi täiskasvanueas, mis hõlmab järgmisi ühe ensüümi vead:sterooli 27-hydroxylase (esitades võimalikult cerebrotendinous xanthomatosis, ctx) puudulikkus;2- (või alfa-) methylacyl-coa racemase (amacr) puudulikkus; - kolesterooli 7 alfa-hydroxylase (cyp7a1) puudus.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkootikumid luuhaiguste raviks - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastilised ained - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastilised ained - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
voxzogo
biomarin international limited - vosoritide - achondroplasia - narkootikumid luuhaiguste raviks - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Eesti -
eesti -
Ravimiamet
nintedanib stada pehmekapsel
stada arzneimittel ag - nintedaniib - pehmekapsel - 150mg 60tk; 150mg 30tk